1 / 58

SEDATION & NEUROMUSCULAR BLOCKADE

SEDATION & NEUROMUSCULAR BLOCKADE. Pediatric Critical Care Medicine Emory University Children’s Healthcare of Atlanta. Objectives. Definition Signs & Symptoms Categories Shock physiology Treatments. Myths. Children don’t feel pain/anxiety; underestimation of pain

Download Presentation

SEDATION & NEUROMUSCULAR BLOCKADE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. SEDATION & NEUROMUSCULAR BLOCKADE Pediatric Critical Care Medicine Emory University Children’s Healthcare of Atlanta

  2. Objectives • Definition • Signs & Symptoms • Categories • Shock physiology • Treatments

  3. Myths • Children don’t feel pain/anxiety; underestimation of pain • Masking symptoms of progressing injury • Side effects: respiratory depression & cardiovascular compromise • Addiction

  4. Truths - Pain • Pathophysiology of pain Tissue damage  release local mediators (bradykinin, substance P, prostoglandins, K+)  heighten nociception  facilitate the communication of painful sensations to the spinal cord & brain Tissue injury  release of histamine & serotonin  increase pain sensitivity in areas surrounding the site of initial injury

  5. Truths - Pain • All nerve pathways for the conduction of painful stimuli & awareness of pain are functional by 24 wk EGA • Failure to manage painful stimuli increases perception of pain for future painful events • Lack of pain control increases the stress responses • Simons SH, van Dijk M. van Lingen RA et al: Randomized controlled trial evaluation effects of morphine on plasma adrenaline/noradrenaline concentration in newborns. Arch. Dis Child Fetal Neonatal Ed. 2005; 90: F36-F40

  6. Truths – Side Effects • Respiratory & hemodynamic compromises • Potentiates with combination with other sedatives & analgesics • Understanding the pharmacokinetics and effects of these agents

  7. Truths - Addiction • Definitions: • Addiction • Tolerance • Dependence • Dependence: • 1/3 pts who received tx>4wks • Continuous infusion: tolerance develops within days • Riss, J.; Cloyd, J.; Gates, J.; Collins, S. (Aug 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.". Acta Neurol Scand118 (2): 69–86. doi:10.1111/j.1600-0404.2008.01004 • Risk factors: • Dependent personality • Short acting benzo • Long-term use of benzo

  8. Sedation – A Continuum • Analgesia • Minimal sedation • Moderate sedation • Deep sedation • General anesthesia

  9. Sedation – A Continuum • Awake/ Drowsy/ Gen. Anest. • Baseline Anxiolysis • Moderate Deep • sedation sedation

  10. Sedation Measurement Tools • Modified Ramsey Score • 0 – unresponsive • 1 – responsive to noxious stimuli • 2 – responsive to touch or name • 3 – calm & cooperative • 4 – restless & cooperative • 5 – agitated • 6 – dangerously agitated & uncooperative

  11. Sedation Measurement Tools • Bispectral Index (Bis) • Measure level of consciousness by algorithmic analysis of EEG • Scale 0 (silent EEG) to 100 (fully awake) • Good tools to use for deep sedation/anesthesia, doesn’t differentiate level of consciousness for moderate to deep sedation • Mason KP et all: Value of bispectral index monitor in defferentiating between moderate and deep Ramsay Sedation Scores in children. Paediatr Anaesth. 2006 Dec; 16 (12):1226-31

  12. Sedative - Hypnotic • Sedation, motion control, and anxiolysis • NO analgesia • Classes • Benzodiazepines • Barbiturates • Chloral hydrate • Diprivan • α –adrenergic agonists

  13. Sedation Neurotransmitters • GABA: inhibitory neurotransmitter in the brain • Glycin: inhibitory neurotransmitter in the spinal cord & brain stem • Glutamate: excitatory receptors

  14. Sedation - Benzodiazepines • Augment GABA & glycin transmission  binding to receptors  influx Cl-  hyper-polarization  resistance to neuronal excitation • BZD bind to receptor complex  enhance GABA binding to its receptors  increase in GABA efficiency • BZD increase the frequency of Cl- channel opening  increase GABA potency

  15. Sedation - Benzodiazepines • Effects: anxiolytic, amnestic, anti-convulsant, hypnotic, sedative, skeletal muscle relaxant • Decrease CMRO2 & CBF • Impair anterograde amnesia, • Affect ventilatory response to both hypoxia & hypercapnea • Potentiate effect with alcohol & narcotics • Decrease both pre & after-load  decrease MAP with min effect on CO

  16. Sedation - Benzodiazepines • Tolerance involves GABAA receptor • Down regulation • Alterations to the subunit configuration • Uncoupling & internalizing of the BZD binding site • Change in gene expression • Others • Paradoxical reaction – disinbition usually in children or older adults with h/o alcohol abuse or ones with underlying aggressive behavior • Rebound insomnia & anxiety after only 7 days • Long lasting memory deficit with long term use • Worsening of depression

  17. Sedation - Benzodiazepines • Withdrawal syndrome • Anxiety, insomnia, nightmares, seizures, psychosis, hyper-reflexia • Post midazolam infusion phenomenon • Slow tapering to decrease withdrawal

  18. Sedation - Benzodiazepines

  19. BZD - Midazolam • Most commonly used sedative • Water soluble (less thrombophlebitis)  less pain with injection • IV, IM, PO, IN, PR, Buccal • Metabolized by P450 (CYP) enzymes & by glucuronide conjugation • Side effects: • Post midazolam infusion phenomenon • A “midazolam infusion syndrome”: delayed arousal hrs to days after discontinuation, associated with high dose infusion • “Hang over”: psychomotor & cognitive function impairment to the next day

  20. BZD - Lorazepam • Highly protein bound, extensively metabolized into inactive forms • Lipophobic  confine in the vascular space • IV, IM, PO, SL • Solvent: polyethylene & propylene glycol hyperosmolar metabolic acidosis with prolonged infusion • Injectable solution contains benzyl alcohol • Uses: • Status epilepticus • Alcohol withdrawal syndrome, catatonia • Anti-emetic

  21. BZD - Diazepam • IV, IM, PO (100% bio-availability), PR (90%) • Highly protein bound, cross BBB & placenta, excrete in stools • Lipophilic  evenly distributed  accumulative effect with repeat doses • High risk of thrombophlebitis, pain with injection • P450 + glucuronidation in liver long t ½ metabolite • Uses: anxiety, insomia, seizure, muscle spasm, restless leg syndrome, alcohol and BZD withdrawal

  22. Sedation - Barbiburates • GABAA receptor (different from BZD)  increases duration of Cl- channel opening  increases GAGA efficacy • Block AMPA receptor (glutamate subtype) • Decrease CMRO2 & CBF • Side effects: myocardial depression, hypotension • Effects: CNS depressants (mild sedation  anesthesia); anxiolytic, hypnotic, anti-convulsants (except Methohexital) • Uses: • Surgical anesthesia • Delirium tremens • Seizures • Insomnia

  23. Sedation - Barbiburates

  24. Sedation - Chloral Hydrate • Sedative & hypnotic: short term use for insomnia • Enhance GABA receptor complex • Tolerance with long term use • Overdose: N/V, convulsion, confusion, irregular breathing, arrhythmias, coma • SV, junctional or ventricular arrhythmias including torsades de pointes • Side effects: rash, gastric discomfort, myocardial depression, hepatic failure • Hyperbilirubinemia: displace bilirubin from albumin sites

  25. Sedation - Chloral Hydrate Alcohol dehydrogenase Chloral Hydrate Trichloroethanol (TCE) T ½ 8-12hr 45% protein bound 30-60 min peak Glucuronidation Trichloroacetate (TCA) T ½ 67 hrs Inc. 3-4X in neonates Displace bili from albumin CNS depression

  26. Sedation - Diprivan • 10% soybean oil, 2.25% glycerol, 1.2% egg phosphatide • Protein bound; metabolized by conjugation in liver + extra hepatic elimination • Potentiate GABAA receptor activity  slow the closing of the Cl-channels • Rapid distribution to peripheral tissue  ultra short effects • T ½ 2-24 hrs

  27. Sedation - Diprivan • Adverse effects: • Pain with injection, pro-bacterial growth, produce green urine • Negative inotrope, potent vasodilitation, bradycardia • Potent respiratory depressant • Deplete trace element (Zinc) in prolonged infusion • “Propofol infusion syndrome” • “Gasping syndrome”

  28. Sedation - α-adrenergic Agonists • α-1 agonist: stimulates phospholipase C activity • Vasoconstriction, mydriasis • Use a vasopressrs, nasal decongestants, eye exam • α-2 agonist: inhibits adenylyl cyclase activity • Reduce brainstem vasomotor center-mediated CNS activation • Use: anti-hypertensive, sedative, opiate & alcohol withdraw • α-2a: sedation, sleep, analgesia, sympatholysis • α-2b: vasoconstriction, anti-shivering, endogenous analgesia

  29. Sedation - α-adrenergic Agonists • Clonidine: α-2: α-1 = 200:1 • Large volume of distribution, long T½ 12-24 hrs • Acts on receptors in the locus coeruleus (stress & panic) • Prevent pre-synaptic release of NE in the sympathetic nervous system  anti-hypertensive • Acts on peripheral α-2  vasoconstriction • Dexmetomidine: α-2: α-1 = 1600:1 • T½ 1.5-3 hrs, ½ excrete unchanged in urine • Min respiratory depression, sedated yet easily aroused • Highly lipophilic, cross BBB • Effective in CV symptoms for cocaine intoxication • Reduce sympathetic activity  decrease HR & BP • Rapid infusion  hypertension due to activation of α-1

  30. Sedation - Ketamine • Dissociate anesthesia (similar in structure of PCP)  hallucigenic, analgesic, amnestic • NMDA (glutamate) antagonist  analgesic; • Binds to opioid receptors (μ & sigma) in high dose • Increases catecholamines release & cholinergic receptor stimulation  bronchodilator, mucous production, increase SVR, HR, CO • Increasse CBF & CRMO2 • Metabolized to Norketamine to excrete in urine

  31. Analgesia • Oucher Scale by Judy Beyer, modified by Wong: self report with faces & numerical pain scale • Pain physiological responses – observational pain scale (OPS) • HR & BP • Measuring level of adrenal stress hormone • COMFORT score: • Behaviors: alertness, facial tension, muscle tone, agitation, movement • Physiologic responses: HR, respiration, BP

  32. Analgesia • Anti-pyretic & non-opioid • Opiod • Methadone

  33. Analgesia – Antipyretic or Non-opioid • Cyclo-oxygenase (COX) 1,2,3: inhibit prostaglandins production (peripheral & central) • Cox 1:protective prostaglandins  preserve gastric lining integrity; maintain normal renal function • Cox 2: inducible by pro-inflammatory cytokines & growth factors; in both brain & spinal cord: nerve transmission for pain & fever • Useful for inflammatory processes (bony or rheumatic)

  34. Analgesia – Antipyretic or Non-opioid • Aspirin: • Alter platelet function; can cause gastric irritant • Ketorolac • Platelet dysfuncion  serious risk of GI bleeding • Trilisate (choline magnesium trisalicylate; ASA like compound) • No SE on platelet • Use in post-op pain or cancer patients • Paracetamone • Central Cox 3, no anti-inflammatory activity • Naproxen • Cox 1 inhibitor

  35. Analgesia - Opioids • Terms: • Agonist • Antagonist • Partial agonist • Receptors: µΚδσ • Inhibit synaptic transmission in CNS and myenteric plexus • Found in pre-synaptic, decrease release of excitatory neurotransmitter for nociceptive stimuli • Coupling with G-protein, regulate trans-membrane signaling by regulate cAMP

  36. Analgesia – Morphine • µ2 agonist: analgesia, sedation, euphoria, resp. depression • K and δ agonist: spinal analgesia, miosis, psychomimetic effects • Glucuronide metabolism  M3G (exrete) & M6G (active metabolites) • Poor lipid solubility, protein binding • SQ, IV, IT, epidural

  37. Analgesia – Morphine • Increase in sensory threshold for pain • Respiratory depression: decrease RR, MV & response to CO2 • Miosis: pupillary constriction via oculomotor nucleus • Decrease stress hormones: ACTH, ADH, prolactin, GH & epi • Uncertain response to N/V: act on chemo-trigger zone + depress vomiting center • Smooth muscle relaxation: directly or via vagus nerve • Increase biliary tract tone  biliary colic • Urinary retention via increase tone in bladder detrusor muscle or vesical sphincter • Histamine release  bronchospasm or CV collapse

  38. Analgesia - Fentanyl • 100X >morphine • Strong agonist at the µ and K • Lipophilic: cross BBB  rapid onset with short duration 2/2 rapid redistribution • Block systemic & pulmonary hemodynamic effect of pain • Prevent biochemical & endocrine stress (catabolic) • Adverse effects: N/V, constipation, dry mouth, somnolence, confusion, anesthesia (weakness), sweating Severe AE: glottic & chest wall rigidity with rapid infusion (>5mcg/kg)

  39. Analgesia – Other Fentanyls • Sufentanil • 5-10x > Fentanyl, most potent opioid in clinical practice • Smaller volume of distribution, faster recovery after prolonged infusion • Alfentanil • 5x < Fentanyl, short duration 5-10 min • Useful for RSI with ICP • Remifentanil • Metabolized by plasma esterase with short t ½ • Potent µ with mild K & δ effects, potent respiratory depression, no histamine release • Similar kinetics in neonates & adults • Very expensive

  40. Analgesia – Other Opioids • Meperidine • K receptor agonist; strong opioidergic, anticholinergic and antispasmodic; Local anesthetic properties – surgical spinal analgesia • Superior to Morphine for billiary spasm or renal colic • Metabolized to normeperidine - twice as toxic • “Serotonin syndrome” with CNS excitatory effects: tremors, ms spasm, myoclonus, psychiatric changes & seizure • Interact with MAOIs  agitation, delirium, headache, convulsions, hyperthermia (Libby Zion Law) • Contraindicated in liver, kidney disease, seizure disorder, enlarged prostate or urinary retention, hypothyroidism, asthma, Addison’s disease.

  41. Analgesia – Other Opioids • Codein • Methylmorphine: analgesic, anti-tussive, anti-diarrheal • Alkaloid found in opium poppy (papaveraceae) • Convert to morphine in the liver by P450 and to active metabolites • Prolonged use  physical dependence & psychologically addictive; mild withdrawal symptoms • Preserve pupillary signs

  42. Analgesia – Other Opioids • Tramadol (Ultram, Tramal) • Weak µ agonist, release serotonin, inhibits reuptake of norepinephrine • Therapy for most neuralgia and chronic pain • Hard to wean due to effects on opioid, serotonin/NE activity • Decrease seizure threshold • Hydromorphone (Dilaudid) • Centrally acting opioid class on µ receptor, 8x > morphine • Water soluble with quick onset • Lack of toxic metabolite, lower dependency, less nausea • Brief but intense withdrawal

  43. Analgesia – Opioid Antagonist • Naloxone • Competitive antagonist with high affinity for µ receptor in CNS  rapid onset of withdrawal • IV with fast onset of action; T½ 30-81 min

  44. Analgesia – Other • Methadone • Acts on opioid receptors without the euphoric effects  prevent narcotic withdrawal syndrome • Binds on NMDA (N-methyl-D-aspartate) antagonist against glutamate  decrease craving for opioids & tolerance

  45. Analgesia – Withdrawal • Neurologic excitability: Sleep disturbances, agitation, tremors, seizures, choreoartheroid movements • GI disturbances: V/D • Autonomic dysfunction: hypertension, tachycardia, tachypnea, fever, frequent yawning, sweating or goose flesh,

  46. Neuromuscular Blockade • Large highly charged water - soluble molecules at physiologic pH can’t cross BBB, placenta, GI • Onset is more rapid & less intense at the laryngeal muscle (vocal cord) & peripheral muscle • Diaphragm is the most resistant to paralysis

  47. Neuromuscular Blockade • Types • Depolarizing: mimic action of acetylcholine • Non-depolarizing: competitively block ACH receptors • Classifications • Short: succinylcholine, mivacurium • Intermediate: atracurium, vecuronium, rocuronium, cisatracurium • Long: pancuronium, doxacurium, pipecuronium

  48. Furhman, 3rd Edition

More Related